Opportunity knocks for software makers




OK, software makers, you're up.

Drug developers need capacity-planning solutions--really good ones that account for resource costs (see related story). And they have to be up to the challenges of increasingly complex clinical trial protocols, including those for adaptive trials, and accurate enough to show cost savings.

Yes, you've provided clinical capacity-planning features within trial management solutions. But now it's time to step it up a notch, says Kenneth Kaitin of the Tufts Center for the Study of Drug Development.

The need is now for capacity-planning solutions based on an accurate understanding of resource costs. Here's your chance to shine.

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.